Biomerica Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37863 BIOMERICA, INC. (949) 645-2111(Registrant’s telephone number, including area code) Securities registered under Section 12(b) of the Exchange Act: Indicate by check whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (paragraph 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit and post such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ The number of shares of the registrant’s common stock outstanding as of January 14, 2026, was 3,020,067. BIOMERICA, INC. INDEXPART IFinancial InformationItem 1.Financial Statements:Condensed Consolidated Balance Sheets (unaudited) – November 30, 2025 and May 31, 20251Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) – Three and Six Months EndedNovember 30, 2025 and 20242Condensed Consolidated Statements of Shareholders’ Equity (unaudited) – Three and Six Months Ended November 30,2025 and 20243Condensed Consolidated Statements of Cash Flows (unaudited) – Six Months Ended November 30, 2025 and 20244Notes to Condensed Consolidated Financial Statements (unaudited)5 - 12Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations13 - 18Item 3.Quantitative and Qualitative Disclosures about Market Risk18Item 4.Controls and Procedures18PART IIOther Information19Item 1.Legal Proceedings19Item 1A.Risk Factors19Item 5.Other Information19Item 6.Exhibits19Signatures20i BIOMERICA, INC. AND SUBSIDIARIESNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) NOTE 1: BASIS OF PRESENTATION Biomerica, Inc. (“Biomerica,” “us,” “we,” “our,”or the“Company”) and its subsidiaries (which includes wholly-owned subsidiaries, Biomericade Mexico and BioEurope GmbH) is a global biomedical technology company that develops, patents, manufactures and markets advanceddiagnostic and therapeutic products used at the point-of-care (physicians’ offices and over-the-counter through drugstores and online) and inhospital/clinicallaboratories for detection and/or treatment of medical conditions and diseases.Our diagnostic test products utilizeimmunoassay technology to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerancesand other medical complications, and to measure the level of specific hormones, antibodies, antigens, or other substances, which may exist inthe human body in extremely small concentrations. Our other existing products are primarily focused on gastrointestinal diseases, foodintolerances, and certain esoteric tests. Our products are designed to enhance the health and well-being of people, while reducing totalhealthcare costs. Our primary focus is the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guidedtherapy (“DGT”) products to treat gastrointestinal diseases, such as irritable bowel syndrome (“IBS”), and other inflammatory diseases. Theseproducts are directed at chronic inflammatory illnesses that are widespread, common, and address very large markets. Instead of broad anddifficult to manage dietary restrictions, our inFoods® IBS product uses a simple blood sample and is designed to identify patient-specific foodsthat, may be causing an abnormally high immune response in the patient, that when removed from the diet may alleviate IBS symptoms such asabdominal pain and cramping, bloating, diarrhea and constipation. A food identified a